Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type


GILEAD SCIENCES   FYE=12 (December)

Annual - Income Statement - Company Specific

Fiscal period2019201820172016201520142013201220112010
Period End Date12/31/201912/31/201812/31/201712/31/201612/31/201512/31/201412/31/201312/31/201212/31/201112/31/2010
Product sales, net22,119.0021,677.0025,662.0029,953.0032,151.0024,474.0010,804.009,398.008,102.367,389.92
Contract sales--------------------
Royalty revenues----------------268.83545.97
Royalty and contract revenue330.00450.00445.00437.00488.00416.00398.00304.00----
Contract and other revenues----------------14.2013.53
Total Revenues22,449.0022,127.0026,107.0030,390.0032,639.0024,890.0011,202.009,702.008,385.397,949.42
Cost of sales4,675.004,853.004,371.004,261.004,006.003,788.002,859.002,471.002,124.411,869.88
Research and development9,106.005,018.003,734.005,098.003,014.002,854.002,120.001,760.001,229.151,072.93
Purchased in-process research and development--------------------
Selling, general and administrative4,381.004,056.003,878.003,398.003,426.002,983.001,699.001,461.001,241.981,044.39
Asset impairment--------------------
Total Operating Expenses18,162.0013,927.0011,983.0012,757.0010,446.009,625.006,678.005,692.004,595.543,987.20
Operating Income (loss)4,287.008,200.0014,124.0017,633.0022,193.0015,265.004,524.004,010.003,789.843,962.22
Interest expense995.001,077.001,118.00964.00688.00412.00307.00361.00205.42108.96
Gain on sale of oncology assets--------------------
Gain on sale of unconsolidated affiliate--------------------
Loss on sale of marketable securities--------------------
Minority interest in joint venture--------------------
Interest and other income, net--------------------
Make-whole payment on convertible debt redemption--------------------
Other income (expense), net1,868.00676.00523.00428.00154.003.00(9.00)(37.00)66.5860.29
Gain on warrant--------------------
Income (loss) before provision for income taxes an and equity in loss of unconso5,160.007,799.0013,529.0017,097.0021,659.0014,856.004,208.003,612.003,651.003,913.55
Provision (benefit) for income taxes(204.00)2,339.008,885.003,609.003,553.002,797.001,151.001,038.00861.951,023.80
State: Current--162.0097.00131.00158.00152.0062.0049.0062.63139.82
State: Deferred--(17.00)(20.00)28.00(21.00)(30.00)(22.00)(15.00)(17.45)17.46
Foreign: Current--175.0054.00261.00212.0085.0046.0028.0039.9243.09
Foreign: Deferred--(21.00)60.00(77.00)(51.00)(30.00)(20.00)(2.00)4.040.45
Federal: Current--1,716.008,817.003,351.003,568.002,810.001,156.001,003.00704.41852.82
Federal: Deferred--324.00(123.00)(85.00)(313.00)(190.00)(71.00)(25.00)68.39(29.85)
Equity in loss of unconsolidated affiliate--------------------
Loss before cumulative effect of change in accounting principle--------------------
Cumulative effect of change in accounting principle--------------------
Consolidated Net Income (Loss)5,364.005,460.004,644.0013,488.0018,106.0012,059.003,057.002,574.002,789.062,889.75
Net loss attributable to noncontrolling interest(22.00)5.0016.00(13.00)(2.00)(42.00)(18.00)(18.00)(14.58)(11.51)
Net income (loss) attributable to common stockholders5,386.005,455.004,628.0013,501.0018,108.0012,101.003,075.002,592.002,803.642,901.26
Loss before cumulative effect of change in accounting principle--------------------
Cumulative effect of change in accounting principle- Basic--------------------
Net income (loss) per share - Basic4.244.203.5410.0812.377.952.011.711.811.69
Loss before cumulative effect of change in accounting principle--------------------
Cumulative effect of change in accounting principle- Diluted--------------------
Net income (loss) per share - Diluted4.224.173.519.9411.917.351.811.641.771.66
Shares used in per share calculation - basic1,270.001,298.001,307.001,339.001,464.001,522.001,529.001,515.001,549.811,712.12
Shares used in per share calculation - diluted1,277.001,308.001,319.001,358.001,521.001,647.001,695.001,583.001,580.241,746.79